# Sagent Pharmaceuticals, Inc.

Sagent Pharmaceuticals, Inc. is a company headquartered in Schaumburg, IL, United States.

## Company overview

- **Legal name:** Sagent Pharmaceuticals, Inc.
- **Former names in filing history:** Sagent Holding Co. (2009-06-02 to 2011-04-25); NHS PHARMACEUTICALS (2006-06-26 to 2006-06-26)
- **Classification:** Company
- **Industry (SIC):** 2834 — Pharmaceutical Preparations
- **Headquarters:** Schaumburg, IL, United States
- **Incorporated in:** DE
- **Fiscal year end:** December 31
- **SEC CIK:** 0001369786

## About

Sagent Pharmaceuticals, Inc. is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001369786, and its reported industry is Pharmaceutical Preparations. In 10-K filed on 2016-03-07, it reported net income of USD -21,882,000; total assets of USD 349,732,000 for the fiscal period ended 2015-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2015 (period ended 2015-12-31)

- **Net income:** -$21.9M (USD -21,882,000)
- **Total assets:** $349.7M (USD 349,732,000)
- **Cash and equivalents:** $29.0M (USD 28,962,000)

### FY2014 (period ended 2014-12-31)

- **Net income:** $39.9M (USD 39,881,000)
- **Total assets:** $381.5M (USD 381,488,000)
- **Cash and equivalents:** $55.6M (USD 55,633,000)
- **Later filings:** Net income, Total assets: shown as originally filed; later filings report different values for the same periods.

### FY2013 (period ended 2013-12-31)

- **Net income:** $29.6M (USD 29,594,000)
- **Total assets:** $310.2M (USD 310,208,000)
- **Cash and equivalents:** $42.3M (USD 42,332,000)
- **Operating cash flow:** $49.6M (USD 49,551,000)

### FY2012 (period ended 2012-12-31)

- **Net income:** -$16.8M (USD -16,817,000)
- **Total assets:** $172.3M (USD 172,315,000)
- **Cash and equivalents:** $27.7M (USD 27,687,000)
- **Operating cash flow:** -$20.1M (USD -20,122,000)

## Recent SEC filings

- Form 8-K — filed 2016-08-29 — period 2016-08-29 — FORM 8-K
- Form 10-Q — filed 2016-08-05 — period 2016-06-30 — SGNT-Q2-2016
- Form 8-K — filed 2016-07-11 — period 2016-07-10 — 8-K
- Form 8-K — filed 2016-06-22 — period 2016-06-17 — FORM 8-K
- Form 8-K — filed 2016-06-16 — period 2016-06-15 — FORM 8-K
- Form 8-K — filed 2016-06-10 — period 2016-06-08 — FORM 8-K
- Form 8-K — filed 2016-05-13 — period 2016-05-10 — 8-K
- Form 10-Q — filed 2016-05-03 — period 2016-03-31 — FORM 10-Q
- Form 8-K — filed 2016-05-03 — period 2016-05-03 — FORM 8-K
- Form DEF 14A — filed 2016-04-29 — period 2016-06-08 — DEF 14A
- Form 8-K — filed 2016-04-06 — period 2016-04-01 — FORM 8-K
- Form 8-K — filed 2016-03-28 — period 2016-03-22 — FORM 8-K

---

Updated: 2026-10-23T20:13:49Z

Canonical page: https://altss.com/profile/sagent-pharmaceuticals-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology